Researchers at Umeå University have identified two human cell proteins, NUP98 and NUP153, that play a crucial role in how ...

Rgenta Therapeutics, a clinical-stage biotechnology company pioneering the development of a new class of oral small molecules targeting RNA and RNA regulation for oncology and neurological disorders, ...

The latest experiments carried out by the Curiosity Rover bring us closer than ever to knowing whether life once existed on ...

Rgenta Therapeutics, a clinical-stage biotechnology company pioneering the development of a new class of oral small molecules targeting RNA and RNA regulation ...

On February 16, Franklin Equity said the biotechnology industry has entered 2026 on a firmer footing following an extended ...

Eli Lilly LLY announced a definitive agreement to acquire Kelonia Therapeutics in a deal valued at up to $7 billion, ...

Bristol Myers Squibb BMY and Gilead Sciences GILD are two leading biotech players with diversified portfolios and a strong ...

Remix Therapeutics (Remix), a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address the underlying drivers of disease, today announced the ...

Some people living with HIV develop antibodies capable of neutralizing many different strains of the virus. New research links this to immune responses that occur early in infection. The findings, ...

A new study analyzed piRNA — first discovered in 2006 — as a strong predictor of short-term survival in older patients. It ...

In “Why Do We Exist?” Hakeem Oluseyi explores how life may emerge to move energy through matter—and why Earth is the perfect ...

Eluciderm, Inc., a clinical-stage pharmaceutical company developing small molecule therapeutics to promote healing and regenerative repair of injured tissue, announced today that it received the Wound ...